Measuring breathing effort in patients with idiopathic pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with idiopathic pulmonary fibrosis (IPF) to assess their inspiratory effort through nasal pressure measurements. The research aims to better understand the progression of lung damage in IPF, a condition characterized by severe respiratory failure and a median survival of three years post-diagnosis. By evaluating the inspiratory effort, the study seeks to identify potential correlations with disease progression and acute exacerbations. Participants will undergo radiological evaluations to confirm their diagnosis and suitability for the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients treated in Center for Rare diseases of Azienda Ospedaliero-Universitaria Policlinico di Modena will be considered eligible if satisfying the following inclusion criteria:

* Patient with IPF and UIP pattern
* Need for radiological evaluation through HRCT

Exclusione criteria

* Age below 18
* Pregnancy
* Inability to sign informed consent
* COPD
* Neuromuscular diseases
* Evidence of IPF acute exacerbation

Where it's running

• Azienda Ospedaliero Universitaria Policlinico di Modena
  Modena, Italy Recruiting

Study contacts

• Study coordinator: Roberto Tonelli, MD
• Email: roberto.tonelli@unimore.it
• Phone: +390594225934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HOXB7 and related lung and blood biomarkers in pulmonary fibrosis

  This pilot study will test whether levels of HOXB7 and other molecules in lung tissue and blood exosomes can serve as biomarkers in adults with pulmonary fibrosis.

  Recruiting University of Modena and Reggio Emilia · Modena · NCT07373288

• Rehabilitation counseling for patients with interstitial lung disease

  This study is trying to see if rehabilitation counseling can help improve the physical and emotional well-being of patients with idiopathic pulmonary fibrosis.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06815185

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• Advanced imaging to see how immunosuppression affects lung fibrosis activity

  This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT07572383

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Home monitoring for patients with pulmonary fibrosis

  This study tests if using home monitoring and video calls can help people with pulmonary fibrosis manage their condition as well as or better than regular clinic visits.

  Recruiting at 11 sites Erasmus Medical Center · Amsterdam and 10 other locations · NCT06883448

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.